Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Diphenhydramine vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Allergic rhinitis,Urticaria,Pruritus,Insomnia (OTC sleep aid),Motion sickness,Parkinsonism (off-label for extrapyramidal symptoms)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life 4-8 hours in adults; prolonged in hepatic impairment (up to 20 hours) and elderly.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2C9, and CYP2C19; undergoes N-demethylation and N-oxidation; first-pass metabolism is extensive.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily renal (90-95% as metabolites, <5% unchanged). Minor biliary/fecal elimination (<5%).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
98-99% bound, primarily to albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd 3-5 L/kg (wide distribution, high tissue binding).
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 50-70% (first-pass metabolism). IM: 100% (assumed). IV: 100%.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No specific dose adjustment for GFR. Use with caution in severe renal impairment (Cr Cl <10 m L/min) due to potential accumulation; consider reducing dose or extending interval.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider 25% of usual dose or avoid.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Children 2-5 years: 6.25 mg orally every 4-6 hours (max 37.5 mg/day). Children 6-11 years: 12.5-25 mg orally every 4-6 hours (max 150 mg/day). Children ≥12 years: 25-50 mg orally every 4-6 hours (max 300 mg/day).
Not approved for pediatric patients <18 years; safety and efficacy not established.
Elderly patients (>65 years): initially 25 mg orally at bedtime, increase if needed; maximum 50 mg/day. Avoid as first-line antihistamine due to anticholinergic adverse effects (confusion, falls).
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Not recommended for use in neonates or premature infants due to potential association with sudden infant death syndrome (SIDS) and paradoxical CNS excitation.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Causes significant sedation, impairing ability to drive or operate machinery; anticholinergic effects may exacerbate narrow-angle glaucoma, urinary retention, hyperthyroidism, hypertension, and prostatic hypertrophy; avoid concurrent use with alcohol or other CNS depressants.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to diphenhydramine or any antihistamine; acute asthma attack; concurrent MAOI therapy; breastfeeding (large doses may decrease milk production and cause infant sedation); narrow-angle glaucoma (absolute); urinary retention (absolute).
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No significant food interactions. Grapefruit juice may theoretically inhibit CYP2D6 metabolism, but clinical relevance is minimal. Avoid alcohol due to additive CNS depression.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: No increased risk of major congenital anomalies based on large cohort studies, though a weak association with oral clefts has been reported (RR ~1.3-1.5). Second trimester: No known risk. Third trimester: Near term, high doses may cause oxytocin-like effects; once-daily antihistamine effect with minimal fetal risk. Avoid use during late third trimester due to potential for uterine hyperstimulation.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Breastfeeding safety: Compatible, but caution advised due to potential for sedation and irritability in the infant. M/P ratio: Not clinically established; oral bioavailability is low but infant exposure is minimal at typical maternal doses. Avoid use in nursing mothers if alternative antihistamines with better safety profiles are available.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dosing adjustments recommended based on pregnancy-induced pharmacokinetic changes. However, due to increased volume of distribution and altered hepatic metabolism in pregnancy, some clinicians may use lower starting doses for efficacy. Monitor for excessive sedation and adjust accordingly.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Diphenhydramine is a first-generation antihistamine with strong anticholinergic effects; avoid in elderly due to increased risk of confusion, falls, and urinary retention. Rapid IV administration can cause hypotension and arrhythmias; give slow IV push. Use with caution in patients with glaucoma, prostate hypertrophy, or asthma. Onset of sedation within 30-60 minutes; useful for acute dystonias (e.g., from antipsychotics) at 25-50 mg IM/IV. Not recommended for children <2 years due to risk of respiratory depression.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Do not drive or operate heavy machinery until you know how this drug affects you, as it causes drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and fall risk.,Dry mouth, blurred vision, and constipation are common; drink water and use sugar-free gum for dry mouth.,If you have difficulty urinating or eye pain, stop the medication and seek medical help.,Do not exceed recommended dose; overdose can cause seizures, hallucinations, or serious heart problems.,Take with food if stomach upset occurs, but avoid grapefruit juice as it may affect drug metabolism.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Diphenhydramine, a first-generation antihistamine with significant central nervous system (CNS) depressant effects, and clonazepam, a benzodiazepine that enhances GABA-A receptor activity, produce additive CNS depression when co-administered. This synergistic effect increases the risk of excessive sedation, psychomotor impairment, respiratory depression, and potential for falls, especially in elderly patients. Clinically, patients may experience profound drowsiness, confusion, ataxia, and impaired cognitive and motor function, which can lead to accidents or worsen sleep-disordered breathing."
"Concurrent use of diphenhydramine and butalbital results in additive central nervous system (CNS) depression due to their overlapping sedative-hypnotic properties. Diphenhydramine, a first-generation antihistamine, antagonizes histamine H1 receptors and crosses the blood-brain barrier, while butalbital, a barbiturate, enhances GABA-A receptor activity. This synergism can lead to excessive sedation, impaired cognitive and motor function, respiratory depression, and increased risk of accidental injury or overdose, particularly in elderly patients or those with hepatic impairment."
"Cevimeline, a muscarinic agonist used for xerostomia, can inhibit the metabolism of diphenhydramine by competitively blocking cytochrome P450 (CYP) 2D6 and 3A4 enzymes. This results in reduced clearance of diphenhydramine, leading to elevated plasma concentrations and increased risk of anticholinergic side effects such as sedation, confusion, dry mouth, blurred vision, and urinary retention. Clinically, patients may experience enhanced and prolonged central nervous system depression and anticholinergic toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Diphenhydramine vs ABSTRAL, answered by our medical review team.
Diphenhydramine is a Antihistamine that works by Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Diphenhydramine and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Diphenhydramine is: 25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Diphenhydramine and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Diphenhydramine is classified as Category C. First trimester: No increased risk of major congenital anomalies based on large cohort studies, though a weak association with oral clefts has been reported (RR ~1.3-1.5). Second t. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.